Research programme: proteasome inhibitors - Pono PharmaAlternative Names: Macrocyclic vinyl ketone - Pono Pharma; Proteasome inhibitors research programme - Pono Pharma; Syrbactins - Pono Pharma
Latest Information Update: 16 Jul 2016
At a glance
- Originator Pono Pharma
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 30 Apr 2013 Early research in Cancer in USA (unspecified route)